Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
October 16, 2007

Microbix to Manufacture Adenoviruses to Further ALS Therapy Development Institute’s Research

  • The ALS Therapy Development Institute (ALS TDI) inked a deal with Microbix Biosystems for the manufacture of adenoviral stocks to be tested in the mouse model of amyotrophic lateral sclerosis (ALS).

    “The relationship with Microbix will allow the R&D team at the ALS TDI to test dozens of adenoviral constructs to knock down the expression of genes or over-express genes that may impact disease progression in the mouse model of ALS,” says Steve Perrin, CSO at the ALS TDI.

    Under the terms of the one-year contract, Microbix will use its technology to produce, purify, and characterize various adenoviruses created to carry therapies to sites of ALS pathology.

  • You’re all set! Thank you for subscribing to GEN Highlights.